<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Intern Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">Intern. Med</journal-id>
      <journal-id journal-id-type="doi">10.2169/internalmedicine.55.6806</journal-id>
      <journal-title-group>
        <journal-title>Internal Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0918-2918</issn>
      <issn pub-type="epub">1349-7235</issn>
      <publisher>
        <publisher-name>The Japanese Society of Internal Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27746441</article-id>
      <article-id pub-id-type="pmc">5109571</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Bone Histology of Two Cases with Osteomalacia Related to Low-dose Adefovir</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Hiramatsu</surname>
            <given-names>Rikako</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ubara</surname>
            <given-names>Yoshifumi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sawa</surname>
            <given-names>Naoki</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hasegawa</surname>
            <given-names>Eiko</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kawada</surname>
            <given-names>Masahiro</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Imafuku</surname>
            <given-names>Aya</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sumida</surname>
            <given-names>Keiichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hoshino</surname>
            <given-names>Junichi</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takaichi</surname>
            <given-names>Kenmei</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Nephrology Center, Toranomon Hospital, Japan</aff>
        <aff id="aff2"><label>2</label>Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan</aff>
      </contrib-group>
      <author-notes>
        <fn>
          <p>Correspondence to Dr. Yoshifumi Ubara, <email>ubara@toranomon.gr.jp</email></p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>15</day>
        <month>10</month>
        <year>2016</year>
      </pub-date>
      <volume>55</volume>
      <issue>20</issue>
      <fpage>3013</fpage>
      <lpage>3019</lpage>
      <history>
        <date date-type="received">
          <day>7</day>
          <month>11</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p><!--CREATIVE COMMONS-->The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We performed a bone histomorphometric analysis in two patients demonstrating Fanconi syndrome with hypophosphatemia, adefovir-related bone disease and chronic hepatitis B infection. Both patients had osteomalacia, but showed two different histological patterns. The osteoid volume of the patient without risedronate increased with [(osteoid volume/ bone volume)&#xD7;100=18.6%]. However, the osteoid volume of the patient receiving risedronate without vitamin D analogue showed a greater increase of 53.8%. In both patients bone pain and hypophosphatemia subsided soon after the discontinuation of adefovir and the administration of phosphate derivative. These findings show that bisphosphonate may worsen this disease when this drug is administered without a vitamin D analogue. </p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>adefovir-related bone disease</kwd>
        <kwd>osteomalacia</kwd>
        <kwd>chronic hepatitis B infection</kwd>
        <kwd>risedronate</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Introduction</title>
      <p>Adefovir dipivoxil (ADV) is used to treat (chronic) infection associated with hepatitis B virus (HBV). It acts by blocking reverse transcriptase, an enzyme that is crucial for the spread of HBV. However, Fanconi syndrome and bone disease have been reported to occur even in patients taking a low daily dose of ADV (10 mg). In 2010, Wong et al. reported a 40-year-old man in whom Fanconi syndrome and bone disease occurred after ADV was administered at 10 mg daily for chronic hepatitis B infection, and whose bone pain improved after the cessation of ADV and the administration of phosphate supplementation. His bone disease was clinically diagnosed as adefovir-related osteomalacia, based on symptoms of widespread bone pain and the detection of microfractures by magnetic resonance imaging (<xref rid="B1" ref-type="bibr">1</xref>). Similar cases have also been reported by Girgis and Kim in 2011 and 2012, respectively (<xref rid="B2" ref-type="bibr">2</xref>,<xref rid="B3" ref-type="bibr">3</xref>). Since a close relation between Fanconi syndrome and osteomalacia has been histologically demonstrated in previous studies (<xref rid="B4" ref-type="bibr">4</xref>), adefovir-related bone disease has been diagnosed to be osteomalacia based only on the clinical features without examining the bone histology, even though osteomalacia requires a histological diagnosis (<xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>).</p>
      <p>We encountered two patients with chronic hepatitis B infection in whom adefovir-related bone disease was diagnosed to be osteomalacia based on bone histomorphometry. We found that one patient had been treated with a second-generation bisphosphonate (BP) (risedronate) to treat bone pain by another doctor. The histological changes of the bone in Adefovir-related osteomalacia with or without risedronate treatment are herein described and discussed.</p>
    </sec>
    <sec>
      <title>Case Reports</title>
      <sec>
        <title>Case 1</title>
        <p>In August 2012, a 67-year-old Japanese woman was admitted to our hospital for an evaluation of severe pain in the bilateral ankles to distal tibiae, knee joints, and ribs. Hepatitis due to HBV infection was diagnosed in 1983. Lamivudine was started in 2006, but her hepatitis did not subside, so low-dose ADV was added (10 mg daily) in March 2008. Two months later, the HBV-DNA polymerase titer became negative. In June 2012, generalized bone pain suddenly occurred without any precipitating cause and then worsened.</p>
        <p>On admission, the patient was 158 cm tall and weighed 63.8 kg. The laboratory data are shown in <xref ref-type="table" rid="t001">Table 1</xref>.</p>
        <table-wrap id="t001" orientation="portrait" position="float">
          <label>Table 1.</label>
          <caption>
            <p>Laboratory Test.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead style="border-top:solid thin; border-bottom:solid thin;">
              <tr>
                <th align="left" rowspan="1" colspan="1">Laboratory test</th>
                <th align="left" rowspan="1" colspan="1">normal range</th>
                <th align="left" rowspan="1" colspan="1">case 1</th>
                <th align="left" rowspan="1" colspan="1">case 2</th>
              </tr>
            </thead>
            <tbody style="border-top:solid thin; border-bottom:solid thin;">
              <tr style="border-top:solid thin; border-bottom:solid thin;">
                <td align="center" rowspan="1" colspan="1">
                  <bold>Serum</bold>
                </td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Asparate aminotransferase</td>
                <td rowspan="1" colspan="1">13-33 (IU/L)</td>
                <td rowspan="1" colspan="1">24</td>
                <td rowspan="1" colspan="1">16</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Alanine aminotransferase</td>
                <td rowspan="1" colspan="1">6-27 (IU/L)</td>
                <td rowspan="1" colspan="1">11</td>
                <td rowspan="1" colspan="1">13</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Alkaline phosphatase</td>
                <td rowspan="1" colspan="1">117-350 (IU/L)</td>
                <td rowspan="1" colspan="1">819</td>
                <td rowspan="1" colspan="1">961</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Total protein</td>
                <td rowspan="1" colspan="1">6.9-8.4 (mg/dL)</td>
                <td rowspan="1" colspan="1">5.8</td>
                <td rowspan="1" colspan="1">7.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Albumine</td>
                <td rowspan="1" colspan="1">3.9-5.2 (mg/dL)</td>
                <td rowspan="1" colspan="1">2.5</td>
                <td rowspan="1" colspan="1">3.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Uric nitrogen</td>
                <td rowspan="1" colspan="1">8-21 (mg/dL)</td>
                <td rowspan="1" colspan="1">16</td>
                <td rowspan="1" colspan="1">17</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Creatinine</td>
                <td rowspan="1" colspan="1">0.4-0.8 (mg/dL)</td>
                <td rowspan="1" colspan="1">0.6</td>
                <td rowspan="1" colspan="1">0.8</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Uric acid</td>
                <td rowspan="1" colspan="1">2.5-7.0 (mg/dL)</td>
                <td rowspan="1" colspan="1">1.3</td>
                <td rowspan="1" colspan="1">1.2</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Sodium</td>
                <td rowspan="1" colspan="1">139-146 (mmol/L)</td>
                <td rowspan="1" colspan="1">147</td>
                <td rowspan="1" colspan="1">145</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Pottasium</td>
                <td rowspan="1" colspan="1">3.7-4.8 (mmol/L)</td>
                <td rowspan="1" colspan="1">3.2</td>
                <td rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Chloride</td>
                <td rowspan="1" colspan="1">101-109 (mmol/L)</td>
                <td rowspan="1" colspan="1">119</td>
                <td rowspan="1" colspan="1">112</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Calcium</td>
                <td rowspan="1" colspan="1">8.7-10.1 (mg/dL)</td>
                <td rowspan="1" colspan="1">8.1</td>
                <td rowspan="1" colspan="1">9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Phosphate</td>
                <td rowspan="1" colspan="1">2.8-4.6 (mg/dL)</td>
                <td rowspan="1" colspan="1">2.3</td>
                <td rowspan="1" colspan="1">1.2</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Glucose</td>
                <td rowspan="1" colspan="1">70-110 (mg/dL)</td>
                <td rowspan="1" colspan="1">76</td>
                <td rowspan="1" colspan="1">79</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Magnesium</td>
                <td rowspan="1" colspan="1">1.4-1.9 (mEq/L)</td>
                <td rowspan="1" colspan="1">1.8</td>
                <td rowspan="1" colspan="1">1.9</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Intact-parathyroid hormone</td>
                <td rowspan="1" colspan="1">10-65 (pg/mL)</td>
                <td rowspan="1" colspan="1">37</td>
                <td rowspan="1" colspan="1">48</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">1,25 (OH) 2D3</td>
                <td rowspan="1" colspan="1">20-60 (pg/mL)</td>
                <td rowspan="1" colspan="1">20.8</td>
                <td rowspan="1" colspan="1">23.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">25 (OH) D</td>
                <td rowspan="1" colspan="1">9-33.9 (ng/L)</td>
                <td rowspan="1" colspan="1">22.6</td>
                <td rowspan="1" colspan="1">20.2</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Bone-specific alkaline phosphatase</td>
                <td rowspan="1" colspan="1">9.6-35.4 (U/mL)</td>
                <td rowspan="1" colspan="1">95.1</td>
                <td rowspan="1" colspan="1">100</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Osteocalcine</td>
                <td rowspan="1" colspan="1">2.5-13 (ng/mL)</td>
                <td rowspan="1" colspan="1">8.5</td>
                <td rowspan="1" colspan="1">9.6</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">TRAP-5b</td>
                <td rowspan="1" colspan="1">170-590 (mU/dL)</td>
                <td rowspan="1" colspan="1">669</td>
                <td rowspan="1" colspan="1">988</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">FGF23</td>
                <td rowspan="1" colspan="1">&lt;10 (pg/mL)</td>
                <td rowspan="1" colspan="1">&lt;10</td>
                <td rowspan="1" colspan="1">&lt;10</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">pH</td>
                <td rowspan="1" colspan="1">7.35-7.45</td>
                <td rowspan="1" colspan="1">7.36</td>
                <td rowspan="1" colspan="1">7.35</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Bicarbonate (HCO3<sup>-</sup>)</td>
                <td rowspan="1" colspan="1">22-26 (mmol/L)</td>
                <td rowspan="1" colspan="1">18</td>
                <td rowspan="1" colspan="1">19</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">eGFR</td>
                <td rowspan="1" colspan="1">90-150 (mL/min)</td>
                <td rowspan="1" colspan="1">71.1</td>
                <td rowspan="1" colspan="1">63.8</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Anion gap</td>
                <td rowspan="1" colspan="1">10-14 (mEq/L)</td>
                <td rowspan="1" colspan="1">10</td>
                <td rowspan="1" colspan="1">14</td>
              </tr>
              <tr style="border-top:solid thin; border-bottom:solid thin;">
                <td align="center" rowspan="1" colspan="1">
                  <bold>Urine</bold>
                </td>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">
                  <bold>pH</bold>
                </td>
                <td rowspan="1" colspan="1">4.5-7.5</td>
                <td rowspan="1" colspan="1">5.3</td>
                <td rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Glucose</td>
                <td rowspan="1" colspan="1">&lt;0.1 (g/day)</td>
                <td rowspan="1" colspan="1">4.9</td>
                <td rowspan="1" colspan="1">2.1</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Protein</td>
                <td rowspan="1" colspan="1">&lt;0.1 (g/day)</td>
                <td rowspan="1" colspan="1">0.75</td>
                <td rowspan="1" colspan="1">0.54</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Calcium</td>
                <td rowspan="1" colspan="1">40-200 (mg/day)</td>
                <td rowspan="1" colspan="1">62.8</td>
                <td rowspan="1" colspan="1">23.3</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Phosphate</td>
                <td rowspan="1" colspan="1">0.5-0.9 (g/day)</td>
                <td rowspan="1" colspan="1">2.2</td>
                <td rowspan="1" colspan="1">0.98</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">&#x3B2;2microglobuline</td>
                <td rowspan="1" colspan="1">130-329 (&#xB5;g/L)</td>
                <td rowspan="1" colspan="1">72,038</td>
                <td rowspan="1" colspan="1">50,391</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Aminoaciduria</td>
                <td rowspan="1" colspan="1">minus</td>
                <td rowspan="1" colspan="1">plus</td>
                <td rowspan="1" colspan="1">plus</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1">Tmp/GFR</td>
                <td rowspan="1" colspan="1">0.8-1.3 (%)</td>
                <td rowspan="1" colspan="1">0.52</td>
                <td rowspan="1" colspan="1">0.74</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>The findings of generalized aminoaciduria, renal glucosuria, hypophosphatemia, hypouricemia, and proximal tubular metabolic acidosis with a normal anion gap indicated the presence of Fanconi syndrome. Potential causative disorders such as multiple myeloma were excluded. Radiographs of the lower tibial shaft showed narrow radiolucent lines measuring 2 to 4 mm in width with sclerotic borders, which are called Looser zones and indicate the presence of pseudofractures. These were more prominent in the right leg (<xref ref-type="fig" rid="g001">Fig. 1a</xref>). Bone scintigraphy with <sup>99m</sup>Tc-labeled methylene diphosphonate (MDP) demonstrated a high uptake in the bilateral ankles to distal tibiae (including the pseudofractures of the lower tibial shaft), knees, and ribs (<xref ref-type="fig" rid="g001">Fig. 1b</xref>). When the bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DEXA), the right forearm and right hip had a BMD that was 2.0 and 2.4 SD below the female mean peak bone mass (T-score), respectively. The serum p level became less than 2.0 mg/dL at 20 months after the administration of ADV, while bone pain occurred at 52 months, and bone biopsy was done at 56 months (<xref ref-type="fig" rid="g001">Fig. 1c</xref>).</p>
        <fig id="g001" orientation="portrait" position="float">
          <label>Figure 1.</label>
          <caption>
            <p>a: Radiograph of the right lower tibial shaft displays narrow radiolucent lines measuring 2 to 4 mm in width with sclerotic borders (arrow), thus indicating a pseudofracture pattern known as Looser zones. b: Bone scintigraphy with <sup>99m</sup>Tc-labeled methylene diphosphonate (MDP) demonstrates a high uptake in the bilateral ankles to distal tibiae (including the pseudofracture of the lower tibial shaft), knees, and ribs. c: Clinical course.</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3013-g001"/>
        </fig>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>In September 2012, a 65-year-old Japanese woman was admitted to our hospital for an evaluation of severe pain in the bilateral ankles, knees, and ribs. Hepatitis due to HBV infection had been diagnosed in 1982. Lamivudine was started in 2000, but did not suppress the disease activity, so ADV was added at a dose of 10 mg daily in October 2006. The HBV-DNA polymerase titer became negative in July 2010. In addition to pain of the bilateral hip, ankle, and knee joints, a bilateral femoral neck fracture (<xref ref-type="fig" rid="g002">Fig. 2a</xref>) suddenly occurred without any precipitating cause in June 2011. Bilateral femoral head replacement was performed, and risedronate was started at a dose of 17.5 mg weekly, and it was administered for 14 months. However, her bone pain did not subside.</p>
        <fig id="g002" orientation="portrait" position="float">
          <label>Figure 2.</label>
          <caption>
            <p>a: A bilateral femoral neck fracture (arrows) occurred suddenly without any precipitating cause. b: Clinical course.</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3013-g002"/>
        </fig>
        <p>On admission, the patient was 143 cm tall and weighed 45.3 kg. The laboratory data are shown in <xref ref-type="table" rid="t001">Table 1</xref>. Generalized aminoaciduria, renal glucosuria, hypophosphatemia, hypouricemia, and proximal tubular metabolic acidosis with a normal anion gap indicated a diagnosis of Fanconi syndrome. Possible causative disorders such as multiple myeloma were also excluded in this patient. Radiography did not show a definite pseudofracture pattern, but bone scintigraphy with MDP demonstrated a very high uptake in the bilateral ankles, knees, hips, and ribs, corresponding to the sites of pain. DEXA showed the BMD of the right forearm to be 3.9 SD below the female mean peak bone mass (T-score). The serum p level became less than 2.0 mg/dL at 36 months after the administration of ADV, a bone fracture occurred at 56 months, and a bone biopsy was done at 70 months (<xref ref-type="fig" rid="g002">Fig. 2b</xref>).</p>
      </sec>
      <sec>
        <title>Bone histomorphometry</title>
        <p>After obtaining informed consent, double tetracycline labeling was done (with a schedule of 3 days on-7 days off-3 days on-7 days off using doxycycline at 200 mg daily), and a right iliac crest bone biopsy was performed to examine the bone disease in these patients. A histomorphometric analysis was performed using undecalcified thin (5 &#x3BC;m) sections of the bone biopsy specimen stained by the Villanueva method. This analysis was carried out by Mrs. Akemi Ito of the Ito Bone Science Institute (Niigata, Japan) (<xref rid="B5" ref-type="bibr">5</xref>). The sections were observed with an epifluorescence microscope under ultraviolet light at a magnification of &#xD7;160, and the histomorphometric parameters were measured directly using an image analysis system linked to a computer (ASBMR Histomorphometry Nomenclature) (<xref rid="B6" ref-type="bibr">6</xref>).</p>
      </sec>
    </sec>
    <sec>
      <title>Results</title>
      <sec>
        <title>Case 1</title>
        <p>There was a marked decrease of cancellous bone that had been replaced by adipose tissue, while the cortical bone was preserved (<xref ref-type="fig" rid="g003">Fig. 3a</xref> and <xref ref-type="table" rid="t002">Table 2</xref>). The cancellous bone adjacent to the cortical bone was evaluated, and it showed features that were diagnostic of osteomalacia (<xref ref-type="fig" rid="g003">Fig. 3b</xref>). There was no tetracycline labeling along most of the trabecular bone surfaces and the osteoid volume had greatly increased [(osteoid volume/ bone volume)&#xD7;100=18.6%]. The ratio of fibrous tissue volume to total volume was 0.0%, while the ratio of total bone volume to total tissue volume had decreased to 11.8% (normal, 20.8&#xB1;1.5%) and the ratio of eroded surface to total bone surface had increased to 44.7% (normal: 5.6&#xB1;1.9%). The osteoclast numbers near the walls of the resorption cavities had also increased to 1.66/mm.</p>
        <fig id="g003" orientation="portrait" position="float">
          <label>Figure 3.</label>
          <caption>
            <p>a: Cancellous bone has markedly decreased and has been replaced by adipose tissue, but the cortical bone is preserved (A: natural, B: polarization, C: fluorescent). b: Cancellous bone adjacent to the cortical bone shows features of osteomalacia (case 1). The red area shows osteoid (large arrow) and the green area is mineralized bone (small arrow) (A: natural, B: fluorescent).</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3013-g003"/>
        </fig>
        <table-wrap id="t002" orientation="portrait" position="float">
          <label>Table 2.</label>
          <caption>
            <p>A Histomorphometrical Analysis of Right Iliac Crest.</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead style="border-top:solid thin; border-bottom:solid thin;">
              <tr>
                <th align="left" rowspan="1" colspan="1"/>
                <th align="left" rowspan="1" colspan="1">Bone parameter</th>
                <th align="left" rowspan="1" colspan="1">Abbreviation</th>
                <th align="left" rowspan="1" colspan="1">Unit</th>
                <th align="left" rowspan="1" colspan="1">case 1</th>
                <th align="left" rowspan="1" colspan="1">case 2</th>
                <th align="left" rowspan="1" colspan="1">normal range</th>
              </tr>
            </thead>
            <tbody style="border-top:solid thin; border-bottom:solid thin;">
              <tr>
                <td rowspan="1" colspan="1">Bone volume</td>
                <td rowspan="1" colspan="1">Bone volume/tissue volume</td>
                <td rowspan="1" colspan="1">BV/TV</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">11.8085</td>
                <td rowspan="1" colspan="1">49.4742</td>
                <td rowspan="1" colspan="1">19.56&#xB1;5.62</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Trabecular thickness</td>
                <td rowspan="1" colspan="1">Tb. Th</td>
                <td rowspan="1" colspan="1">&#xB5;m</td>
                <td rowspan="1" colspan="1">108.8064</td>
                <td rowspan="1" colspan="1">272.2858</td>
                <td rowspan="1" colspan="1">131.3&#xB1;28.1</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Wall thickness</td>
                <td rowspan="1" colspan="1">W. Th</td>
                <td rowspan="1" colspan="1">&#xB5;m</td>
                <td rowspan="1" colspan="1">NM</td>
                <td rowspan="1" colspan="1">NM</td>
                <td rowspan="1" colspan="1">28.29&#xB1;3.74</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteood volume/tissue volume</td>
                <td rowspan="1" colspan="1">OV/TV</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">2.2041</td>
                <td rowspan="1" colspan="1">26.6383</td>
                <td rowspan="1" colspan="1">0.36&#xB1;0.31</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteoid volume/bone volume</td>
                <td rowspan="1" colspan="1">OB/BV</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">18.6653</td>
                <td rowspan="1" colspan="1">53.8426</td>
                <td rowspan="1" colspan="1">1.20&#xB1;0.87</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteoid surface/bone surface</td>
                <td rowspan="1" colspan="1">OS/BS</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">43.4017</td>
                <td rowspan="1" colspan="1">92.0994</td>
                <td rowspan="1" colspan="1">14.0&#xB1;6.64</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteoid thickness</td>
                <td rowspan="1" colspan="1">O. Th</td>
                <td rowspan="1" colspan="1">&#xB5;m</td>
                <td rowspan="1" colspan="1">24.0983</td>
                <td rowspan="1" colspan="1">79.5337</td>
                <td rowspan="1" colspan="1">8.31&#xB1;1.99</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteoblasts number/bone surface</td>
                <td rowspan="1" colspan="1">N. Ob/BS</td>
                <td rowspan="1" colspan="1">N/mm</td>
                <td rowspan="1" colspan="1">2.8621</td>
                <td rowspan="1" colspan="1">1.2146</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">Resorption</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">Eroded surface/bone surface</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">ES/BS</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">%</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">44.7544</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">7.2764</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">3.66&#xB1;1.69</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Osteoclasts number/bone surface</td>
                <td rowspan="1" colspan="1">N. Oc/BS</td>
                <td rowspan="1" colspan="1">N/mm</td>
                <td rowspan="1" colspan="1">1.657</td>
                <td rowspan="1" colspan="1">0.3599</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Fibrous volume/tissue volume</td>
                <td rowspan="1" colspan="1">Fb. V/TV</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
              </tr>
              <tr>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">Mineralization</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">Mineral apposition rate</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">MAR</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">&#xB5;m/day</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">0</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">0</td>
                <td style="border-top:solid thin;" rowspan="1" colspan="1">0.477&#xB1;0.078</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Double labeled surface/bone surface</td>
                <td rowspan="1" colspan="1">dLS/BS</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Single labeled surface/bone surface</td>
                <td rowspan="1" colspan="1">sLS/BS</td>
                <td rowspan="1" colspan="1">%</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Bone formation rate/bone surface</td>
                <td rowspan="1" colspan="1">BFR/BS</td>
                <td rowspan="1" colspan="1">mm<sup>3</sup>/mm<sup>2</sup>/year</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0.010&#xB1;0.008</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Bone formation rate/bone volume</td>
                <td rowspan="1" colspan="1">BFR/BV</td>
                <td rowspan="1" colspan="1">%/year</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">16.2&#xB1;12.5</td>
              </tr>
              <tr>
                <td rowspan="1" colspan="1"/>
                <td rowspan="1" colspan="1">Activation frequency</td>
                <td rowspan="1" colspan="1">Acf</td>
                <td rowspan="1" colspan="1">N/year</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1">0</td>
                <td rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>NM: Not measured</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>Almost all of the cancellous bone of case 2 was preserved with trabecular connections, but a reduction of the cortical bone was seen (<xref ref-type="fig" rid="g004">Fig. 4a</xref>). The cancellous bone also showed features that were diagnostic of osteomalacia (<xref ref-type="fig" rid="g004">Fig. 4b</xref>), with no tetracycline labeling along most trabecular bone surfaces and the osteoid volume being greatly increased [(osteoid volume/ bone volume)&#xD7;100=53.8%]. The ratio of fibrous tissue volume to total volume was 0.0%, the ratio of total bone volume to total tissue volume had increased to 49.5% (normal, 20.8&#xB1;1.5%), and the ratio of eroded surface to total bone surface was elevated to 7.3% (normal: 5.6&#xB1;1.9%). The number of osteoclasts near the walls of the resorption cavities was only 0.35/mm.</p>
        <fig id="g004" orientation="portrait" position="float">
          <label>Figure 4.</label>
          <caption>
            <p>a: In case 2, most cancellous bone is preserved with trabecular connections, but there is a reduction of cortical bone (A: natural, B: polarization, C: fluorescent). b: Cancellous bone also shows changes that are diagnostic of osteomalacia (A: natural, B: fluorescent).</p>
          </caption>
          <graphic xlink:href="1349-7235-55-3013-g004"/>
        </fig>
        <p>On case 2, the osteoid volume had markedly increased, even though total bone volume was preserved in comparison to case 1.</p>
      </sec>
      <sec>
        <title>Clinical course </title>
        <p>ADV was therefore changed to entecavir for both patients and a phosphate derivative was administered at a dose of 900 mg daily. In case 2, risedronate was also discontinued. In case 1, bone pain subsided after 1 month, while laboratory abnormalities (including ALP and bone ALP) returned to normal after 10 months. In case 2, bone pain subsided after 3 months, and the laboratory data normalized after 12 months.</p>
      </sec>
    </sec>
    <sec>
      <title>Discussion</title>
      <p>The diagnosis of osteomalacia requires a bone histomorphometric analysis, and osteomalacia is a disorder characterized by the defective mineralization of newly formed bone matrix that results in an increase in the osteoid volume. It is one of the low-turnover bone diseases, since double tetracycline labeling is absent or very weak along most trabecular bone surfaces, and osteoblasts are usually scant. Therefore, controlling resorption by osteoclasts may contribute to the maintenance of bone volume in osteomalacia (<xref rid="B4" ref-type="bibr">4</xref>).</p>
      <p>Various other causes have been suggested to cause the onset of osteomalacia in older individuals, including a dietary deficiency of vitamin D and a decreased synthesis of vitamin D reflecting minimal exposure to sunlight (<xref rid="B7" ref-type="bibr">7</xref>). Osteomalacia has also been reported in patients with gastrointestinal disease such as gastrectomy. Patients with a Billroth II gastrectomy were at a greater risk than those with a Billroth I procedure because of the exclusion of the duodenum (<xref rid="B8" ref-type="bibr">8</xref>). Drugs such as rifampicin, phenytoin, and phenobarbital also have been reported to induce osteomalacia, since they increase vitamin D catabolism via hepatic enzyme activation (<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>). Osteomalacia associated with Fanconi syndrome has been thought to result from hypophosphatemia, low circulating 1,25-dihydroxyvitamin D, renal insufficiency, and chronic acidosis due to bicarbonate loss (<xref rid="B11" ref-type="bibr">11</xref>). Tumor-induced osteomalacia (TIO) is characterized by hypophosphatemia, an increased urinary loss of phosphate as a result of reduced tubular phosphate reabsorption, and it is caused by fibroblast growth factor 23 (FGF23) (<xref rid="B12" ref-type="bibr">12</xref>). There is a report of osteomalacia treated with bisphosphonate (alendronate) without vitamin D. Over the next 21 months, the bone pain worsened, and multiple fractures occurred. Bone histology from the transiliac biopsy samples showed osteomalacia. Bisphosphonate might therefore worsen this disease (<xref rid="B13" ref-type="bibr">13</xref>).</p>
      <p>In conclusion, we performed a bone first histomorphometric analysis in two patients with adefovir-related bone disease. Both patients had a bone histology consistent with osteomalacia, and showed very low turnover bone without new bone formation. The osteoid volume in the patient treated with bisphosphonate was greater than in the other patient. These findings show that bisphosphonate may worsen this disease via interference of the efficient acquisition of hydroxyapatite when this drug is administered without a vitamin D analogue.</p>
    </sec>
    <sec>
      <title>The authors state that they have no Conflict of Interest (COI).</title>
    </sec>
    <sec>
      <title>Financial Support</title>
      <p>This study was funded by the Okinaka Memorial Institute for Medical Research. We thank Akemi Ito of the Ito bone histomorphometry institute for performing the histomorphometric analysis.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <label>1.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>T</given-names></name>, <name><surname>Girgis</surname><given-names>CM</given-names></name>, <name><surname>Ngu</surname><given-names>MC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B</article-title>. <source>J Clin Endocrinol Metab</source>
<volume>95</volume>: <fpage>479</fpage>-<lpage>480</lpage>, <year>2010</year>.<pub-id pub-id-type="pmid">20133467</pub-id></mixed-citation>
      </ref>
      <ref id="B2">
        <label>2.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girgis</surname><given-names>CM</given-names></name>, <name><surname>Wong</surname><given-names>T</given-names></name>, <name><surname>Ngu</surname><given-names>MC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Hypophosphataemic osteomalacia in patients on adefovir dipivoxil</article-title>. <source>J Clin Gastroenterol</source>
<volume>45</volume>: <fpage>468</fpage>-<lpage>473</lpage>, <year>2011</year>.<pub-id pub-id-type="pmid">20661153</pub-id></mixed-citation>
      </ref>
      <ref id="B3">
        <label>3.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name>, <name><surname>Sung</surname><given-names>DH</given-names></name>, <name><surname>Min</surname><given-names>YK</given-names></name></person-group>
<article-title>Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review</article-title>. <source>J Bone Mine Metab</source>
<volume>31</volume>: <fpage>240</fpage>-<lpage>246</lpage>, <year>2013</year>.</mixed-citation>
      </ref>
      <ref id="B4">
        <label>4.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubara</surname><given-names>Y</given-names></name>, <name><surname>Tagami</surname><given-names>T</given-names></name>, <name><surname>Suwabe</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>A patient with symptomatic osteomalacia associated with Fanconi syndrome</article-title>. <source>Mod Rheumatol</source>
<volume>15</volume>: <fpage>207</fpage>-<lpage>212</lpage>, <year>2005</year>.<pub-id pub-id-type="pmid">17029065</pub-id></mixed-citation>
      </ref>
      <ref id="B5">
        <label>5.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanizawa</surname><given-names>T</given-names></name>, <name><surname>Itoh</surname><given-names>A</given-names></name>, <name><surname>Uchiyama</surname><given-names>T</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Yamamoto</surname><given-names>N</given-names></name></person-group>
<article-title>Changes in cortical width with bone turnover in the three different endosteal envelopes of the ilium in postmenopausal osteoporosis</article-title>. <source>Bone</source>
<volume>25</volume>: <fpage>493</fpage>-<lpage>499</lpage>, <year>1999</year>.<pub-id pub-id-type="pmid">10511118</pub-id></mixed-citation>
      </ref>
      <ref id="B6">
        <label>6.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parfitt</surname><given-names>AM</given-names></name>, <name><surname>Drezner</surname><given-names>MK</given-names></name>, <name><surname>Glorieux</surname><given-names>FH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee</article-title>. <source>J Bone Mineral Res</source>
<volume>2</volume>: <fpage>595</fpage>-<lpage>610</lpage>, <year>1987</year>.</mixed-citation>
      </ref>
      <ref id="B7">
        <label>7.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>PJ</given-names></name>, <name><surname>Ang</surname><given-names>L</given-names></name>, <name><surname>Eastwood</surname><given-names>JB</given-names></name>, <name><surname>Maxwell</surname><given-names>JD</given-names></name></person-group>
<article-title>Clinical and histological spectrum of osteomalacia among Asian in South London</article-title>. <source>Q J Med</source>
<volume>83</volume>: <fpage>439</fpage>-<lpage>448</lpage>, <year>1992</year>.<pub-id pub-id-type="pmid">1448545</pub-id></mixed-citation>
      </ref>
      <ref id="B8">
        <label>8.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>SK</given-names></name>, <name><surname>Dash</surname><given-names>SC</given-names></name>, <name><surname>Tiwari</surname><given-names>SC</given-names></name>, <name><surname>Agarwal</surname><given-names>SK</given-names></name>, <name><surname>Saxena</surname><given-names>S</given-names></name>, <name><surname>Fishbane</surname><given-names>S</given-names></name></person-group>
<article-title>Bone histology in patients with nephrotic syndrome and normal renal function</article-title>. <source>Kidney Int</source>
<volume>55</volume>: <fpage>1912</fpage>-<lpage>1919</lpage>, <year>1999</year>.<pub-id pub-id-type="pmid">10231454</pub-id></mixed-citation>
      </ref>
      <ref id="B9">
        <label>9.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>W</given-names></name>, <name><surname>Erooga</surname><given-names>MA</given-names></name>, <name><surname>Brown</surname><given-names>J</given-names></name>, <name><surname>Stamp</surname><given-names>TC</given-names></name></person-group>
<article-title>Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis</article-title>. <source>J R Soc Med</source>
<volume>75</volume>: <fpage>533</fpage>-<lpage>536</lpage>, <year>1982</year>.<pub-id pub-id-type="pmid">7086805</pub-id></mixed-citation>
      </ref>
      <ref id="B10">
        <label>10.</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bikle</surname><given-names>DD</given-names></name></person-group>
<article-title>Drug-induced osteomalacia</article-title>. In: <source>Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism</source>. <edition>4th ed.</edition>
<person-group><name name-style="western"><surname>Favus</surname><given-names>MJ</given-names></name>, Ed. </person-group><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>, <publisher-loc>Chicago</publisher-loc>, <year>1999</year>: <fpage>343</fpage>-<lpage>346</lpage>.</mixed-citation>
      </ref>
      <ref id="B11">
        <label>11.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>BL</given-names></name>, <name><surname>Wynne</surname><given-names>AG</given-names></name>, <name><surname>Wilson</surname><given-names>DM</given-names></name>, <name><surname>Fitzpatrick</surname><given-names>LA</given-names></name></person-group>
<article-title>Osteomalacia associated with adult Fanconi's syndrome: clinical and diagnostic features</article-title>. <source>Clin Endocribol</source>
<volume>43</volume>: <fpage>479</fpage>-<lpage>490</lpage>, <year>1995</year>.</mixed-citation>
      </ref>
      <ref id="B12">
        <label>12.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukumoto</surname><given-names>S</given-names></name></person-group>
<article-title>Diagnostic modalities for FGF23-producing tumors in patients with tumor-induced osteomalacia</article-title>. <source>Endocrinol Metab (Seoul)</source>
<volume>29</volume>: <fpage>136</fpage>-<lpage>143</lpage>, <year>2014</year>.<pub-id pub-id-type="pmid">25031885</pub-id></mixed-citation>
      </ref>
      <ref id="B13">
        <label>13.</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cundy</surname><given-names>T</given-names></name>, <name><surname>Michigami</surname><given-names>T</given-names></name>, <name><surname>Tachikawa</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reversible deterioration in hypophosphatasia caused by renal failure with bisphosphonate treatment</article-title>. <source>J Bone Miner Res</source>
<volume>30</volume>: <fpage>1726</fpage>-<lpage>1737</lpage>, <year>2015</year>.<pub-id pub-id-type="pmid">25736332</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
